HC Wainwright set a $73.00 target price on Uniqure (NASDAQ:QURE) in a report issued on Monday morning, Stock Target Advisor reports. The brokerage currently has a buy rating on the biotechnology company’s stock.
Other equities research analysts have also recently issued research reports about the company. SunTrust Banks increased their price target on Everbridge to $87.00 and gave the company a buy rating in a report on Tuesday, May 7th. Zacks Investment Research raised SCHNEIDER ELEC /ADR from a hold rating to a buy rating and set a $20.00 price target for the company in a report on Friday, July 5th. Robert W. Baird assumed coverage on Uniqure in a report on Thursday, March 28th. They issued an outperform rating and a $85.00 price target for the company. Cantor Fitzgerald increased their price target on Cerner from $75.00 to $85.00 and gave the company an overweight rating in a report on Monday. Finally, Piper Jaffray Companies set a $80.00 price target on Canopy Growth and gave the company a buy rating in a report on Friday, April 12th. One investment analyst has rated the stock with a sell rating and thirteen have given a buy rating to the company. The company presently has an average rating of Buy and a consensus price target of $77.00.
Shares of NASDAQ:QURE traded down $1.61 during midday trading on Monday, hitting $68.65. The company had a trading volume of 512,228 shares, compared to its average volume of 605,296. Uniqure has a twelve month low of $21.98 and a twelve month high of $82.49. The company has a current ratio of 9.51, a quick ratio of 9.51 and a debt-to-equity ratio of 0.38. The stock has a market capitalization of $2.66 billion, a PE ratio of -29.34 and a beta of 1.05. The firm’s 50-day moving average is $71.56.
In other Uniqure news, CEO Matthew C. Kapusta sold 8,000 shares of the firm’s stock in a transaction on Wednesday, June 19th. The stock was sold at an average price of $77.45, for a total transaction of $619,600.00. Following the completion of the sale, the chief executive officer now owns 409,407 shares of the company’s stock, valued at $31,708,572.15. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Christian Klemt sold 1,546 shares of the firm’s stock in a transaction on Tuesday, April 16th. The stock was sold at an average price of $57.18, for a total value of $88,400.28. Following the sale, the insider now directly owns 54,539 shares of the company’s stock, valued at approximately $3,118,540.02. The disclosure for this sale can be found here. In the last three months, insiders have sold 23,546 shares of company stock valued at $1,556,820. 2.91% of the stock is owned by insiders.
Several hedge funds and other institutional investors have recently modified their holdings of the company. Harvest Group Wealth Management LLC acquired a new stake in shares of Uniqure in the first quarter valued at $26,000. Advisor Group Inc. grew its stake in shares of Uniqure by 5.3% in the fourth quarter. Advisor Group Inc. now owns 9,966 shares of the biotechnology company’s stock valued at $288,000 after buying an additional 502 shares in the last quarter. Pearl River Capital LLC acquired a new stake in shares of Uniqure in the first quarter valued at $32,000. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. grew its stake in shares of Uniqure by 14.7% in the first quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 5,045 shares of the biotechnology company’s stock valued at $301,000 after buying an additional 648 shares in the last quarter. Finally, Legal & General Group Plc grew its stake in shares of Uniqure by 264.2% in the fourth quarter. Legal & General Group Plc now owns 965 shares of the biotechnology company’s stock valued at $28,000 after buying an additional 700 shares in the last quarter. 60.10% of the stock is owned by institutional investors and hedge funds.
Uniqure Company Profile
uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. It engages in developing AMT-061, a gene therapy that is in Phase III clinical trial for the treatment of hemophilia B; AMT-060, which is in Phase I/II clinical trial to treat hemophilia B; AMT-130, a gene therapy for the treatment of Huntington's disease; and AMT-126, for the treatment of heart failure.
Featured Story: What is the downside to momentum investing?
Receive News & Ratings for Uniqure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure and related companies with MarketBeat.com's FREE daily email newsletter.